BioLineRx perks up 7% on Rodman bullish call

• Thinly traded nano cap BioLineRx (BLRX +7.3%) is up on more than a 4x surge in volume on the heels of Rodman & Renshaw's initiation of coverage with a Buy rating and $3 (154% upside) price target.
• The company's lead product candidate is Phase 2-stage cancer therapeutic BL-8040.